Stock Events

Stock Events

Cadrenal Therapeutics 

$4.21
21
+$0+0% Tuesday 04:00

Statistics

Day High
6.62
Day Low
4.21
52W High
-
52W Low
-
Volume
31
Avg. Volume
-
Mkt Cap
8.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Next
-1.55
-1.47
-1.39
-1.31
Expected EPS
-1.33
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-21.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CVKD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech company that develops treatments for cardiovascular diseases, directly competing with Cadrenal's focus on heart-related therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a wide range of heart disease treatments, making it a direct competitor in the cardiovascular therapeutic area.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a strong portfolio in cardiovascular drugs, competing in the same market as Cadrenal Therapeutics.
Merck
MRK
Mkt Cap214.76B
Merck produces several leading cardiovascular treatments, positioning it as a competitor in the heart disease market.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a significant presence in the cardiovascular disease treatment space, competing with Cadrenal Therapeutics.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is known for its extensive cardiovascular drug portfolio, making it a key competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division, offers treatments for cardiovascular conditions, competing with Cadrenal.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has been expanding its cardiovascular treatment offerings, positioning it as a competitor to Cadrenal.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing focus on cardiovascular diseases, making it a competitor in the same therapeutic area as Cadrenal.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a diverse portfolio that includes cardiovascular treatments, competing with Cadrenal Therapeutics in this space.

About

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Show more...
CEO
ISIN
US1276362076

Listings

XNAS
US
CVKD
BOATS
BOATS
CVKD.BOATS

0 Comments

Share your thoughts

FAQ

What is Cadrenal Therapeutics stock price today?▼
The current price of CVKD.BOATS is $4.21 USD — it has increased by +0% in the past 24 hours. Watch Cadrenal Therapeutics stock price performance more closely on the chart.
What is Cadrenal Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cadrenal Therapeutics stocks are traded under the ticker CVKD.BOATS.
What is Cadrenal Therapeutics market cap?▼
Today Cadrenal Therapeutics has the market capitalization of 8.74M
When is the next Cadrenal Therapeutics earnings date?▼
Cadrenal Therapeutics is going to release the next earnings report on May 07, 2026.
What were Cadrenal Therapeutics earnings last quarter?▼
CVKD.BOATS earnings for the last quarter are -1.31 USD per share, whereas the estimation was -1.55 USD resulting in a +15.48% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cadrenal Therapeutics revenue for the last year?▼
Cadrenal Therapeutics revenue for the last year amounts to 0 USD.
What is Cadrenal Therapeutics net income for the last year?▼
CVKD.BOATS net income for the last year is -21.3M USD.
When did Cadrenal Therapeutics complete a stock split?▼
Cadrenal Therapeutics has not had any recent stock splits.